Enorama Pharma Ownership

Stocks . Sweden . 
Stock . Enorama Pharma AB
ERMA Stock  SEK 2.69  0.17  5.94%   
The market capitalization of Enorama Pharma AB is kr89.44 Million. Enorama Pharma AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 78.21 percent of Enorama Pharma AB outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enorama Pharma AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Enorama Stock Ownership Analysis

About 78.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.92. Enorama Pharma AB had not issued any dividends in recent years. The entity had 1726:1687 split on the 29th of October 2018. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden. To learn more about Enorama Pharma AB call Mats Rnngard at 46 7 08 72 82 50 or check out https://www.enorama.se.

Enorama Pharma Outstanding Bonds

Enorama Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enorama Pharma AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enorama bonds can be classified according to their maturity, which is the date when Enorama Pharma AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Morgan Stanley 3971 Corp Bond
US61744YAL20		View
Valero Energy Partners Corp Bond
US91914JAA07		View
AerCap Global Aviation Corp Bond
US00773HAA59		View

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enorama Stock Analysis

When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY